Literature DB >> 2458871

Multiple sclerosis: effect of myelin basic protein on interleukin 1, interleukin 2 production and interleukin 2 receptor expression in vitro.

K Selmaj1, Z Nowak, H Tchórzewski.   

Abstract

The production of interleukin 1 (IL-1) and interleukin 2 (IL-2) by peripheral blood mononuclear cells (PBMC) stimulated with human myelin basic protein (MBP) was assessed in vitro in multiple sclerosis (MS) patients in relapse, patients with other neurological diseases (OND) and healthy subjects. Myelin basic protein significantly increased both IL-1 and IL-2 production by PBMC from MS patients during relapse when compared to OND patients or healthy controls. The most efficient concentration of MBP for the induction of IL-1 and IL-2 was 50 micrograms/ml. The optimal IL-1 production occurred after 48 h of PBMC culture and optimal IL-2 production after 72 h of PBMC culture. Anti-Tac monoclonal antibody (MoAb) was used to study IL-2 receptor expression on the same sample of PBM used for IL-2 study in MS patients in relapse. In addition IL-2 receptor expression was studied in PBMC from chronic progressive MS patients. In both MS groups IL-2 receptor expression on PBMC stimulated with MBP appeared higher than in control groups, but these differences were not statistically significant. IL-2 receptor expression on cerebrospinal fluid lymphocytes (CSF-L) either unstimulated or MBP-stimulated was, however, significantly higher in both MS groups when compared to OND patients. These results confirm the presence of activated lymphocytes in the CSF of MS patients during active stages of disease and suggest that this activation may be related to expansion of MBP specific cells.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2458871      PMCID: PMC1541579     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  27 in total

1.  Mechanisms in multiple sclerosis.

Authors:  B Waksman
Journal:  Nature       Date:  1985 Nov 14-20       Impact factor: 49.962

2.  Selective in vitro growth of T lymphocytes from normal human bone marrows.

Authors:  D A Morgan; F W Ruscetti; R Gallo
Journal:  Science       Date:  1976-09-10       Impact factor: 47.728

3.  In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases.

Authors:  R P Lisak; B Zweiman
Journal:  N Engl J Med       Date:  1977-10-20       Impact factor: 91.245

4.  Contra-IL 2; a suppressor lymphokine that inhibits IL 2 activity.

Authors:  T Maki; S Satomi; M Gotoh; A P Monaco
Journal:  J Immunol       Date:  1986-05-01       Impact factor: 5.422

Review 5.  Myelin basic protein: structure, function and antigenic determinants.

Authors:  G A Hashim
Journal:  Immunol Rev       Date:  1978       Impact factor: 12.988

6.  The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes.

Authors:  T A Waldmann
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

7.  A quantitation of myelin-associated glycoprotein and myelin basic protein loss in different demyelinating diseases.

Authors:  H E Gendelman; G H Pezeshkpour; N J Pressman; J S Wolinsky; R H Quarles; M J Dobersen; B D Trapp; C A Kitt; A Aksamit; R T Johnson
Journal:  Ann Neurol       Date:  1985-09       Impact factor: 10.422

8.  Radioimmunoassay of myelin basic protein in spinal fluid. An index of active demyelination.

Authors:  S R Cohen; R M Herndon; G M McKhann
Journal:  N Engl J Med       Date:  1976-12-23       Impact factor: 91.245

9.  Mechanism of T cell activation. II. Antigen- and lectin-dependent acquisition of responsiveness to TCGF is a nonmitogenic, active response of resting T cells.

Authors:  E L Larsson
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

10.  Cellular hypersensitivity in attacks of multiple sclerosis. I. A comparative study of migration inhibitory factor production and lymphoblastic transformation in response to myelin basic protein in multiple sclerosis.

Authors:  S P Colby; W Sheremata; B Bain; E H Eylar
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

View more
  8 in total

Review 1.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

2.  Immunohistochemical study of vascular injury in acute multiple sclerosis.

Authors:  A J Wakefield; L J More; J Difford; J E McLaughlin
Journal:  J Clin Pathol       Date:  1994-02       Impact factor: 3.411

3.  Type 2 Innate Lymphoid Cells Induce CNS Demyelination in an HSV-IL-2 Mouse Model of Multiple Sclerosis.

Authors:  Satoshi Hirose; Pedram Shafiei Jahani; Shaohui Wang; Ujjaldeep Jaggi; Kati Tormanen; Jack Yu; Mihoko Kato; Omid Akbari; Homayon Ghiasi
Journal:  iScience       Date:  2020-09-10

4.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

5.  Prolonged dynamic clinico-immunological observation of 85 patients with definite multiple sclerosis: first steps towards monitoring process activity.

Authors:  E I Gusev; T L Demina; A N Boiko; B V Pinegin
Journal:  J Neurol       Date:  1994-07       Impact factor: 4.849

6.  Experimental allergic encephalomyelitis in cynomolgus monkeys. Quantitation of T cell responses in peripheral blood.

Authors:  L Massacesi; N Joshi; D Lee-Parritz; A Rombos; N L Letvin; S L Hauser
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

7.  Role of interleukin-2 and herpes simplex virus 1 in central nervous system demyelination in mice.

Authors:  Kevin R Mott; Mandana Zandian; Sariah J Allen; Homayon Ghiasi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

Review 8.  Autoimmune disease and the nervous system. Biochemical, molecular, and clinical update.

Authors:  J E Merrill; M C Graves; D G Mulder
Journal:  West J Med       Date:  1992-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.